Mogamulizumab versus investigator’s choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma

Mogamulizumab, a humanized defucosylated anti-C-C chemokine receptor 4 monoclonal antibody, has been approved in Japan for the treatment of C-C chemokine receptor 4-positive adult T-cell leukemia/lymphoma (ATL). This phase II study evaluated efficacy and safety of mogamulizumab in ATL patients with...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Haematologica
Main Authors: Phillips, Adrienne A., Fields, Paul A., Hermine, Olivier, Ramos, Juan C., Beltran, Brady E., Pereira, Juliana, Wandroo, Farooq, Feldman, Tatyana, Taylor, Graham P., Sawas, Ahmed, Humphrey, Jeffrey, Kurman, Michael, Moriya, Junji, Dwyer, Karen, Leoni, Mollie, Conlon, Kevin, Cook, Lucy, Gonsky, Jason, Horwitz, Steven M.
Formato: Artigo
Idioma:Inglês
Publicado: Ferrata Storti Foundation 2019
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6518882/
https://ncbi.nlm.nih.gov/pubmed/30573506
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2018.205096
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares